Merck Vaccines Supply Interruptions - 7/10/2017
Merck has announced supply interruptions that have impacted availability of several of their vaccines:
•Adult formulation of Vaqta, a hepatitis A vaccine – anticipated return: Q3 2017
•Adult formulation of RecombivaxHB, a hepatitis B vaccine – anticipated return: Q3 2018
•Pediatric formulation of RecombivaxHB, a hepatitis B vaccine – anticipated return: Q1-Q2 2018
Please note that these interruptions do not impact the supply of the pediatric formulation of Vaqta at this time.
During product shortages, CPP does not enforce program purchase guidelines for the affected vaccines. To stay up to date on product availability, refer to the Merck Vaccines Supply Status website.